{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Solid+Neoplasm&page=32", "query": { "condition": "Advanced Solid Neoplasm", "page": 32 }, "page_size": 10 }, "pagination": { "page": 32, "page_size": 10, "total_count": 3387, "total_pages": 339, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Solid+Neoplasm&page=33&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Solid+Neoplasm&page=31&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-12T18:05:34.134Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03286296", "title": "LZM009 to Treat Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor" ], "interventions": [ { "name": "LZM009,recombinant humanized anti-PD-1 monoclonal antibody for injection", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Livzon Pharmaceutical Group Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2017-08-21", "completion_date": "2019-04-23", "has_results": false, "last_update_posted_date": "2019-08-02", "last_synced_at": "2026-11-12T18:05:34.134Z", "location_count": 2, "location_summary": "Grand Rapids, Michigan • San Antonio, Texas", "locations": [ { "city": "Grand Rapids", "state": "Michigan" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03286296" }, { "nct_id": "NCT07541573", "title": "GTB-5550 in Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Tri-specific Killer Engager", "Solid Tumor", "Advanced Solid Tumor" ], "interventions": [ { "name": "GTB-5550", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 175, "start_date": "2026-04-08", "completion_date": "2032-01", "has_results": false, "last_update_posted_date": "2026-04-23", "last_synced_at": "2026-11-12T18:05:34.134Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT07541573" }, { "nct_id": "NCT06710132", "title": "Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumors", "Gastric Cancer", "Non-Small Cell Lung Cancer (NSCLC)", "Pancreatic Cancer", "Pancreatic Ductal Adenocarcinoma (PDAC)" ], "interventions": [ { "name": "M9140", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EMD Serono Research & Development Institute, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 184, "start_date": "2025-01-29", "completion_date": "2027-12-23", "has_results": false, "last_update_posted_date": "2026-10-22", "last_synced_at": "2026-11-12T18:05:34.134Z", "location_count": 8, "location_summary": "Santa Monica, California • Santa Rosa, California • Washington D.C., District of Columbia + 5 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Margate", "state": "Florida" }, { "city": "Greenville", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06710132" }, { "nct_id": "NCT05410145", "title": "A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "KRAS P.G12C" ], "interventions": [ { "name": "D3S-001", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "D3 Bio (Wuxi) Co., Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 442, "start_date": "2022-08-03", "completion_date": "2027-04", "has_results": false, "last_update_posted_date": "2026-09-15", "last_synced_at": "2026-11-12T18:05:34.134Z", "location_count": 7, "location_summary": "Orange, California • Palo Alto, California • Denver, Colorado + 4 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT05410145" }, { "nct_id": "NCT00567931", "title": "1-Methyl-D-Tryptophan in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "1-methyl-d-tryptophan", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2007-10", "completion_date": "2012-09", "has_results": false, "last_update_posted_date": "2014-07-24", "last_synced_at": "2026-11-12T18:05:34.134Z", "location_count": 2, "location_summary": "Tampa, Florida • Richmond, Virginia", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00567931" }, { "nct_id": "NCT06771219", "title": "SLV-154 Treatment of Advanced Cancers", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancer", "Advanced Solid Tumor", "Metastatic Cancer" ], "interventions": [ { "name": "SLV-154", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Solve Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 250, "start_date": "2025-05-14", "completion_date": "2027-11", "has_results": false, "last_update_posted_date": "2026-09-22", "last_synced_at": "2026-11-12T18:05:34.134Z", "location_count": 12, "location_summary": "Newport Beach, California • St Louis, Missouri • East Brunswick, New Jersey + 8 more", "locations": [ { "city": "Newport Beach", "state": "California" }, { "city": "St Louis", "state": "Missouri" }, { "city": "East Brunswick", "state": "New Jersey" }, { "city": "New York", "state": "New York" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06771219" }, { "nct_id": "NCT05385965", "title": "Meaning-Centered Pain Coping Skills Training for Cancer Pain", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Advanced Solid Tumor", "Pain" ], "interventions": [ { "name": "Meaning-Centered Pain Coping Skills Training", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 211, "start_date": "2023-02-09", "completion_date": "2026-05-08", "has_results": false, "last_update_posted_date": "2026-05-12", "last_synced_at": "2026-11-12T18:05:34.134Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05385965" }, { "nct_id": "NCT02936102", "title": "A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "Triple Negative Breast Cancer", "Chordoma and Alveolar Soft Part Sarcoma" ], "interventions": [ { "name": "FAZ053", "type": "DRUG" }, { "name": "PDR001", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 154, "start_date": "2016-10-20", "completion_date": "2024-11-22", "has_results": false, "last_update_posted_date": "2025-11-14", "last_synced_at": "2026-11-12T18:05:34.134Z", "location_count": 2, "location_summary": "New York, New York • Houston, Texas", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02936102" }, { "nct_id": "NCT02748837", "title": "A Study of ERY974 in Patient With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "ERY974", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Chugai Pharmaceutical", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2016-08", "completion_date": "2019-08", "has_results": false, "last_update_posted_date": "2019-08-22", "last_synced_at": "2026-11-12T18:05:34.134Z", "location_count": 7, "location_summary": "Washington D.C., District of Columbia • Tampa, Florida • Boston, Massachusetts + 4 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02748837" }, { "nct_id": "NCT05226507", "title": "A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "Ovarian Cancer", "Ovarian Clear Cell Carcinoma", "Ovarian Clear Cell Tumor", "Ovarian Clear Cell Adenocarcinoma", "Ovarian Endometrioid Adenocarcinoma", "Ovarian Endometrioid Tumor", "ARID1A Gene Mutation" ], "interventions": [ { "name": "NXP800", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nuvectis Pharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2021-12-31", "completion_date": "2025-01-01", "has_results": false, "last_update_posted_date": "2026-08-06", "last_synced_at": "2026-11-12T18:05:34.134Z", "location_count": 19, "location_summary": "Phoenix, Arizona • La Jolla, California • Aurora, Colorado + 16 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Fort Myers", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05226507" } ] }